{"id":683847,"date":"2010-03-05T12:19:00","date_gmt":"2010-03-05T17:19:00","guid":{"rendered":"e2249889-c78b-43e3-9643-b1d7d4aa587b:404032"},"modified":"2010-03-05T12:19:00","modified_gmt":"2010-03-05T17:19:00","slug":"sxc-health-deserves-premium-valuation","status":"publish","type":"post","link":"https:\/\/mereja.com\/index\/683847","title":{"rendered":"SXC Health deserves premium valuation"},"content":{"rendered":"<p><a href=\"http:\/\/www.financialpost.com\/markets\/company\/index.html?symbol=SXC&amp;id=35051\" >SXC Health Solutions Corp.<\/a> is up 21% after Wednesday&#39;s earnings results beat expectations and guidance was also better-than-expected.  <\/p>\n<p>Scott Rattee, CI Capital Markets analyst, thinks the surge has legs, raising his rating to Outperform and target price to US$72 from US$54. &nbsp;<\/p>\n<p>&quot;While FY10 revenue guidance was above consensus expectations, we believe earnings guidance is highly conservative as it only reflects business that SXC has already won, he said in a note to clients.  <\/p>\n<p>&quot;We anticipate SXC to continue to win business during the year.&quot; <\/p>\n<p>With a P\/E multiple of 20.3x, SXC is trading above it health caer peer group average of 18.01x. However, Mr. Rattee continue to target a multiple of 25x for the company.&nbsp; <\/p>\n<p>&quot;We believe SXC&#39;s 12% PE multiple premium to its peers is justified given the company&#39;s long-term organic earnings power, prospect of additional future growth by acquisition, debt free balance sheet and disciplined management team,&quot; he wrote.&nbsp;<\/p>\n<p><a href=\"mailto:dpett@nationalpost.com%20\">David Pett<\/a>  <br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br \/>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/network.nationalpost.com\/NP\/aggbug.aspx?PostID=404032\" width=\"1\" height=\"1\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SXC Health Solutions Corp. is up 21% after Wednesday&#39;s earnings results beat expectations and guidance was also better-than-expected. Scott Rattee, CI Capital Markets analyst, thinks the surge has legs, raising his rating to Outperform and target price to US$72 from US$54. &nbsp; &quot;While FY10 revenue guidance was above consensus expectations, we believe earnings guidance is [&hellip;]<\/p>\n","protected":false},"author":2571,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[4821],"tags":[],"class_list":["post-683847","post","type-post","status-publish","format-standard","hentry","category-news"],"jetpack_featured_media_url":"","jetpack_shortlink":"https:\/\/wp.me\/p9NivD-2RTN","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/683847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/users\/2571"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/comments?post=683847"}],"version-history":[{"count":0,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/683847\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/media?parent=683847"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/categories?post=683847"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/tags?post=683847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}